Producer
Fujifilm Holdings
Fujifilm Holdings Corporation (Tokyo; TSE: 4901; ~¥3.6 trillion revenue) is an aggressively expanding EUV photoresist supplier, targeting approximately 10% of the global EUV resist market through its Electronic Materials division. Fujifilm's EUV resist production facility is at Yoshida-Minami, Shizuoka, Japan. Fujifilm's pivot from consumer photography (film and cameras) to semiconductor chemicals and medical imaging systems is one of the most dramatic industrial transformations in Japanese corporate history — the same company known for photographic film for 90 years is now developing photoresist for 13.5nm EUV lithography. Fujifilm's photochemistry expertise from film manufacturing transferred directly to photoresist development.
2
Inputs supplied
2
Goods downstream
2
Facilities
0
Stories
What they make
2 inputs Fujifilm Holdings supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Fujifilm Holdings makes, pick one to see the full supply chain.
Where they make it
2 facilities
Fujifilm Shizuoka Photoresist Factory →
JPShizuoka Prefecture · manufacturing
Fujifilm primary photoresist manufacturing facility in Shizuoka. New ¥13B building completed November 2025 with AI-driven fine particle inspection system and advanced clean room for EUV photoresist development. Source: https://www.fujifilm.com/us/en/business/semiconductor-materials
Fujifilm Yoshida-Minami Electronics Materials Plant (Shizuoka) →
JPShizuoka Prefecture · manufacturing
Fujifilm's Yoshida-Minami facility in Shizuoka Prefecture is the primary production site for Fujifilm's semiconductor photoresist and electronic materials. Shizuoka Prefecture sits in the Tokai seismic gap — a region where the Philippine Sea Plate subducts beneath Honshu, with a 70-80% probability of a major Tokai earthquake (M8+) within 30 years according to Japan's Headquarters for Earthquake Research Promotion. A Tokai event would be one of the most consequential seismic scenarios for global semiconductor supply chains given the concentration of semiconductor chemical facilities in the region. Source: https://www.fujifilm.com/us/en/business/electronic-materials
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Electronic Materials (Photoresists)
15%Healthcare & Medical Imaging
40%Pharmaceuticals & Bio-CDMO
15%Document Solutions & Printing
20%Cosmetics & Fine Chemicals
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Fujifilm Holdings is simultaneously one of the world's leading manufacturers of medical X-ray film and imaging systems, a major supplier of COVID-19 antiviral drugs (Avigan/favipiravir — approved in Japan and used in clinical trials globally), and an EUV photoresist manufacturer. The photochemistry expertise Fujifilm developed over 90 years manufacturing photographic film — controlling light-sensitive silver halide crystals, polymer matrices, sensitizers, and inhibitors at nanometer scale — directly transferred to semiconductor photoresist development when consumer film demand collapsed after 2000. Fujifilm CEO Shigetaka Komori's strategy of 'second founding' redirected film chemistry into healthcare imaging, cosmetics (CoQ10 via fermentation), pharmaceuticals, and semiconductor materials. The company that made the Fujifilm disposable camera is now a major EUV resist supplier and manufactures influenza drugs — the broadest dual-use portfolio in the materials industry.
Fujifilm Holdings Corporation ↗Origin2023
Fujifilm's transformation is one of the most discussed corporate pivots in business history: the consumer photography film company that faced existential threat from digital cameras redirected its core competency -- precision photochemistry at nanometer scale -- into healthcare imaging, pharmaceuticals, and semiconductor photoresist. CEO Shigetaka Komori's 2004 strategic plan for Fujifilm's 'second founding' identified that film chemistry expertise was transferable to medical imaging contrast agents, anti-aging cosmetics (CoQ10 and collagen synthesis), pharmaceutical manufacturing, and semiconductor photoresist. Fujifilm launched the Astalift skincare brand, built Fujifilm Diosynth Biotechnologies (a major biopharmaceutical CDMO), produced Avigan (favipiravir antiviral), and entered EUV photoresist manufacturing -- all from the silver halide chemistry heritage of photographic film. The company that in 1980 made film for the Fujifilm green disposable camera is in 2024 manufacturing photoresist for the chips inside AI servers. Kodak, the US film competitor, went bankrupt; Fujifilm pivoted and now supplies critical materials across healthcare, semiconductors, and pharma simultaneously.
Fujifilm Holdings Corporation ↗